Compare Smith & Nephew plc (SNN) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Toronto-Dominion Bank — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Toronto-Dominion Bank trades at $114.14 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 16.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Toronto-Dominion Bank for 84 Days on average.
| SNN | TD | |
|---|---|---|
Market Cap | $11.10B | $185.79B |
Volume | 1,051,703 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $37.17 | $124.80 |
52-Week Low | $26.42 | $78.32 |
Typical Hold Time | 120 Days | 84 Days |
Enterprise Value | $14.13B | $559.06B |
Dividend Yield | 2.95% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
TD stock trades at $113.87, down 3.65% on the day, with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.98 exceeding expectations by 13.8%. Recent developments include a $10 billion share buyback program and a $108 billion commitment to Canadian infrastructure. Analyst consensus remains positive with 53% buy ratings and no sell recommendations.
TD presents a mixed investment case with strong profitability metrics (24.9% net margin, 13.6% ROE) offset by bearish technical indicators and volatile cash flow patterns. The stock's current valuation at 17.4x P/E appears reasonable given earnings growth, while the aggressive capital return program signals management confidence. Key risks include interest rate sensitivity and ongoing AML remediation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
